Press Releases - 2007

11/1/2007
Columbia Laboratories to Discuss Third Quarter 2007 financial Results on November 8, 2007 Conference Call
Columbia Laboratories, Inc. (NASDAQ: CBRX) will hold a conference call on November 8, 2007 to discuss financial results of the three- and nine- months period ended September 30, 2007. Robert S. Mills, president and chief executive officer, and James A. Meer, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call.
10/30/2007
Columbia Laboratories to Present at Rodman & Renshaw Healthcare Conference in NYC on November 6, 2007
Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc., (NASDAQ: CBRX) will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York.
10/15/2007
Vaginal Progesterone is Equally Effective and Results in Lower Miscarriage Rates than Injectable Progesterone in Infertility Treatment
A re-analysis of a series of studies of vaginally-administered progesterone versus intramuscular (IM) progesterone injections demonstrates that, when evaluating optimal dosing, clinical results are comparable for early pregnancy support in assisted reproductive technology (ART) cycles, according to data presented today by Paul W. Zarutskie, MD., Zarutskie Fertility and Endocrine Institute, Laguna Niguel, CA. Further, the re-analysis demonstrates that vaginal progesterone is associated with a significantly lower rate of miscarriage than IM progesterone.
10/2/2007
Vaginal Progesterone Gel May Improve Infant Outcomes and Reduce the Rate of Preterm Birth in Women with a Short Cervix in Mid-Pregnancy
For the first time, data show a positive association between the use of vaginal progesterone and infants’ overall health at birth. Babies born to women with high-risk pregnancies treated with PROCHIEVE® 8% (progesterone gel) appear to be less likely to need intensive care than babies born to mothers treated with placebo, Columbia Laboratories, Inc. (NASDAQ:CBRX) announced today.
9/29/2007
Columbia Laboratories Signs U.S. License and Supply Agreement with Ascend Therapeutics to Market Prochieve® 4% Progesterone Gel
Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that it has signed an exclusive, five year license and supply agreement with Ascend Therapeutics, Inc., for the Company’s PROCHIEVE ® 4% progesterone gel, currently indicated and FDA-approved for the treatment of secondary amenorrhea.
9/5/2007
Columbia Laboratories and DesignRxclusive Increase Access to CRINONE 8% Progesterone Gel for Uninsured Patients
Columbia Laboratories, Inc. (NASDAQ: CBRX) announced today it has entered into an agreement with DesignRxclusive LLC to improve access to CRINONE® 8% (progesterone gel) for patients without insurance or whose benefits do not cover this product. Under this agreement, CRINONE 8% will be the only branded vaginal progesterone on the DesignRxclusiveSM formulary.
8/17/2007
Columbia Laboratories to Present at Noble Financial Two Double-O-Seven Conference on August 21, 2007
Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc. (NASDAQ: CBRX), will present at the upcoming Noble Financial Two Double-O-Seven Conference.
8/7/2007
Columbia Laboratories Reports Second Quarter 2007 Financial Results
Columbia Laboratories, Inc. (NASDAQ: CBRX) today reported financial results for the three- and six-month periods ended June 30, 2007.
7/31/2007
Columbia Laboratories to Discuss Second Quarter 2007 Financial Results on August 7, 2007 Conference Call
Columbia Laboratories, Inc. (NASDAQ: CBRX) will hold a conference call on August 7, 2007 to discuss financial results of the three- and six- months period ended June 30, 2007. Robert S. Mills, president and chief executive officer, and James A. Meer, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call.
6/27/2007
Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced positive results from a recently-completed multi-dose pharmacokinetic study of vaginally-administered lidocaine, which the Company is developing to prevent and treat dysmenorrhea.
6/25/2007
Interim Analysis of CRINONE Pregnancy Study to be published in American Society for Reproductive Medicine Journal
Columbia Laboratories, Inc. (NASDAQ: CBRX) announced today that an interim analysis of a pregnancy study comparing the efficacy of CRINONE® 8% (progesterone gel) to compounded intramuscular progesterone (IMP) injections is now available online and will be published in Fertility and Sterility, the journal of the American Society for Reproductive Medicine (ASRM).
6/7/2007
Columbia Laboratories Receives Outstanding Regional Employer Award from RESOLVE: The National Infertility Association
RESOLVE: The National Infertility Association, in partnership with Organon USA Inc., presented Columbia Laboratories, Inc. (NASDAQ: CBRX) with the 2007 Outstanding Regional Employer Award in recognition of the Company’s commitment to its employees and their desire to have the family of their dreams through medical benefits that include coverage for fertility and reproductive issues.
5/23/2007
Columbia Laboratories To Present at FBR Investor Growth Conference on May 31,2007
Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc. (NASDAQ: CBRX), will present at the upcoming Friedman, Billings, Ramsey & Co. Investor Growth Conference.
5/8/2007
Columbia Laboratories Reports Quarter 2007 Financial Results
Columbia Laboratories, Inc. (NASDAQ: CBRX) today reported financial results for the three-month period ended March 31, 2007.
5/2/2007
Columbia Laboratories to Present at UBS Specialty Pharmaceuticals Conference on May 9, 2007
Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc. (NASDAQ: CBRX), will present at the upcoming UBS Global Generic & Specialty Pharmaceuticals Conference.
5/1/2007
Columbia Laboratories to Discuss Quarter 2007 Financial Results on May 8, 2007 Conference Call
Columbia Laboratories, Inc. (NASDAQ: CBRX) will hold a conference call on May 8, 2007 to discuss financial results of the quarter ended March 31, 2007. Robert S. Mills, president and chief executive officer, and James A. Meer, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call.
4/26/2007
Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that preliminary results from the ongoing data analysis of the recently-completed randomized, placebo-controlled, double-blind Phase III clinical trial of PROCHIEVE® 8% (progesterone gel) for the prevention of preterm birth in women with a previous preterm birth earlier than 35 weeks gestation has revealed a possible effect of PROCHIEVE 8% in delaying cervical shortening.
3/15/2007
Columbia Laboratories Reports Fourth Quarter and Year-end 2006 Financial Results
Columbia Laboratories, Inc. (NASDAQ: CBRX) today reported financial results for the three- and twelve-month periods ended December 31, 2006.
2/26/2007
Columbia Laboratories to Discuss Infertility Business Outlook and Strategic Plan for 2007 on March 2, 2007, Conference Call
Columbia Laboratories, Inc. (NASDAQ: CBRX) will hold a conference call on March 2, 2007 to discuss its infertility business outlook and strategic plan for 2007. Robert S. Mills, Columbia’s president and chief executive officer, will host the call.
2/4/2007
Phase III Trial of Progesterone for the Prevention of Preterm Birth in Women with a Previous Preterm Birth Earlier than 35 Weeks Does Not Meet Endpoints
Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced its Phase III clinical trial of progesterone for the prevention of preterm birth in women with a previous preterm birth earlier than 35 weeks gestation did not achieve any reduction in the incidence of preterm birth at week 32, the primary endpoint, or at weeks 28, 35 and 37, secondary endpoints of the study.
1/2/2007
Columbia Laboratories to Discuss of Crinone® (Progesterone Gel) U.S. Marketing Rights on January 4, 2007 Conference Call
Columbia Laboratories, Inc. (NASDAQ: CBRX) will hold a conference call on January 4, 2007 to discuss its recent acquisition of the U.S. marketing rights to CRINONE® (progesterone gel).